Understanding the pharmacokinetics of anxiolytic drugs

Bibliography

• Demyttenaere K, Bruffaerts R, Posada-Villa J, Prevalence, severity, and unmet need for treatment of mental disorders in the World Health Organization World Mental Health Surveys. JAMA 2004;291:2581-90
   PubMed Web of Science ®Google Scholar
• Kessler RC, Ruscio AM, Shear K, Wittchen HU. Epidemiology of anxiety disorders. Curr Top Behav Neurosci 2010;2:21-35
   PubMedGoogle Scholar
• Buckley NA, Dawson AH, Whyte IM, O'Connell DL. Relative toxicity of benzodiazepines in overdose. BMJ 1995;310(6974):219-21
   PubMed Web of Science ®Google Scholar
• Lechevallier-Michel N, Berr C, Fourrier-Réglat A. Incidence and characteristics of benzodiazepine use in an elderly cohort: the EVA study. Therapie 2005;60(6):561-6
   PubMed Web of Science ®Google Scholar
• Gleason PP, Schulz R, Smith NL, Correlates and prevalence of benzodiazepine use in community-dwelling elderly. J Gen Intern Med 1998;13(4):243-50
   PubMed Web of Science ®Google Scholar
• Valenstein M, Taylor KK, Austin K, Benzodiazepine use among depressed patients treated in mental health settings. Am J Psychiatry 2004;161(4):654-61
   PubMed Web of Science ®Google Scholar
• Ballenger JC. Benzodiazepines receptor agonists and antagonists. In: Sadock VA, Sadock BJ, Kaplan HI, editors. Kaplan & Sadock's comprehensive textbook of psychiatry. 7th edition. Lippincott Williams & Wilkins, Philadelphia; 2001. p. 2317-123
   Google Scholar
• Baldwin DS, Anderson IM, Nutt DJ, Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharm 2005;19(6):567-96
   PubMed Web of Science ®Google Scholar
• Nutt D. Overview of diagnosis and drug treatments of anxiety disorders. CNS Spectr 2005;10(1):49-56
   PubMed Web of Science ®Google Scholar
• Woods JH, Katz JL, Winger G. Benzodiazepines: use, abuse and consequences. Pharmacol Rev 1992;44:151-347
   PubMed Web of Science ®Google Scholar
• Marks J. The Benzodiazepines: use, overuse, misuse, abuse. MTP Press, Lancaster; 1985
   Google Scholar
• Gelenberg AJ. Anxiety. In: Bassuk EL, Schoonover SC, Gelenberg AJ, editors. The Practitioner's guide to psychoactive drugs. 2nd edition. Plenum Press, New York; 1983
   Google Scholar
• World Psychiatric Association Task Force Report. Programme on substance abuse. Rational use of benzodiazepines. World Health Organization, Geneva, Switzerland; 1996
   Google Scholar
• Hollister LE. Principles of therapeutic applications of benzodiazepines. In: Smith DE, Wesson DR, editors. The benzodiazepines: current standards for medical practice. MTP Press; Lancaster, PA; 1985. p. 87
   Google Scholar
• Haefely W, Kyburz E, Gerecke M, Recent advances in the molecular pharmacology of benzodiazepine receptors and in the structure activity relationships of their agonists and antagonists. Adv Drug Res 1985;14:165-332
   Google Scholar
• Greenblatt DJ, Divoll M, Abernethy DR, Benzodiazepine kinetics: implications for therapeutics and pharmacogeriatrics. Drug Metab Rev 1983;14:251-92
   PubMed Web of Science ®Google Scholar
• Harvey SC. Hypnotics and sedatives. In: Goodman Gilman A, Goodman LS, Dall TW, editors. Goodman and Gilman's the pharmacological basis of therapeutic. 7th edition. Macmillan, New York; 1985
   Google Scholar
• Mandrioli R, Mercolini R, Raggi MA. Benzodiazepine metabolism: an analytical perspective. Curr Drug Metab 2008;9:827-44
   PubMed Web of Science ®Google Scholar
• Dettli L. Benzodiazepines in the treatment of sleep disorders: pharmacokinetic aspects. Acta Psychiatr Scand 1986;74(Suppl 332):9-19
   Google Scholar
• Greenblatt DJ, Shader RI. The pharmacokinetics of anti-anxiety agents. In: Meltzer HY, editor. Psychopharmacology: the third generation of progress. Raven Press, New York; 1987
   Google Scholar
• Amrein R, Caro JP, Hartmann D, Clinical and psychometric effects of flunitrazepam during the day in relation to pharmacokinetic data. In: Priest RG, Plestcher A, Ward J, editors. Sleep research. MTP Press, Lancaster; 1979. p. 83-98
   Google Scholar
• Jochemsen R, Breimer DD. Pharmacokinetics of benzodiazepines: metabolic pathways and plasma level profiles. Curr Med Res Opin 1984;8(Suppl 4):60-79
   Google Scholar
• Weiershausen U. Pharmacokinetic considerations in the treatment of chronic anxiety. In: Smith DE, Wesson DR, editors. The benzodiazepines: current standards for medical practice. MTP Press; Lancaster, PA; 1985
   Google Scholar
• Greenblatt DJ, Divoll M, Harmatz JS, Pharmacokinetic comparison of sublingual lorazepam with intravenous, intramuscular and oral lorazepam. J Pharm Sci 1982;71:248-52
   PubMed Web of Science ®Google Scholar
• McEvoy GK. editor. American Hospital Formulary Service Drug Information. American Society of Hospital Pharmacists, Bethesda, MD; 1989
   Google Scholar
• Greenblatt DJ, Shader RI, Aberneth DR. Current status of benzodiazepines (first of two parts). N Engl J Med 1983;309:354-8
   PubMed Web of Science ®Google Scholar
• Salzman C. Use of benzodiazepines to control disruptive behavior in inpatients. J Clin Psychiatry 1980;49(Suppl 12):13-15
   Google Scholar
• Shaefer MS. The newer benzodiazepines lorazepam and midazolam. Semin Intervent Radiol 1987;4:173-8
   Google Scholar
• Cook PJ. Benzodiazepine hypnotics in the elderly. Acta Psychiatr Scand 1986;74(Suppl 332):149-58
   Web of Science ®Google Scholar
• Abernethy DR, Greenblatt DJ, Shader RI. Benzodiazepine hypnotic metabolism: drug interactions and clinical implications. Acta Psychiatr Scand 1986;74(Suppl 332):32-8
   PubMedGoogle Scholar
• Greenblatt DJ, Abernethy DR, Morse DS, Clinical importance of the interaction of diazepam and cimetidine. N Engl J Med 1984;310:1639-43
   PubMed Web of Science ®Google Scholar
• Baumann P. Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet 1996;31:444-69
   PubMed Web of Science ®Google Scholar
• Nemeroff CB, De Vane CL, Pollock BG. Newer antidepressants and the cytochrome P450 system. Am J Psychiatry 1996;153:311-20
   PubMed Web of Science ®Google Scholar
• Harvey AT, Preskorn SH. Cytochrome P450 enzymes: interpretations of their interactions with selective serotonin reuptake inhibitors. Part I. J Clin Psychopharmacol 1996;16:273-85
   PubMed Web of Science ®Google Scholar
• Glue P, Banfield C. Psychiatry, psychopharmacology and P450s. Hum Psychopharmacol 1996;11:97-114
   Web of Science ®Google Scholar
• Lane RM. Pharmacokinetic drug interaction potential of selective serotonin reuptake inhibitors. Int Clin Psychopharmacol 1996;11:31-61
   PubMed Web of Science ®Google Scholar
• Verbeeck R, Tjandramaga TB, Verbeckmoes R, Biotransformation and excretion of lorazepam in patients with chronic renal failure. Br J Clin Pharmacol 1976;3:1033-9
   PubMed Web of Science ®Google Scholar
• Smith RB, Kroboth PD, Vanderlugt JT, Pharmacokinetics and pharmacodynamics of alprazolam after oral and IV administration. Psychopharmacology (Berl) 1984;84:452-6
   PubMed Web of Science ®Google Scholar
• Yasui N, Otani K, Kaneko S, A kinetic and dynamic study of oral alprazolam with and without erythromycin in humans: in vivo evidence for the involvement of CYP3A4 in alprazolam metabolism. Clin Pharmacol Ther 1996;59(5):514-19
   PubMed Web of Science ®Google Scholar
• Williams JA, Ring BJ, Cantrell VE, Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab Dispos 2002;30(8):883-91
   PubMed Web of Science ®Google Scholar
• Hirota N, Ito K, Green CE, In vitro/in vivo scaling of alprazolam metabolism by CYP3A4 and CYP3A5 in humans. Biopharm Drug Dispos 2001;22(2):53-71
   PubMed Web of Science ®Google Scholar
• Gupta B, Chopra SC, Mahajan R, Effects of fluoxetine, risperidone and alprazolam on pharmacokinetics of lithium in patients with psychiatric illness. Indian J Pharmacol 2006;38(2):133-4
   Google Scholar
• Calvo G, Garcia-Gea C, Luque A, Lack of pharmacologic interaction between paroxetine and alprazolam at steady state in healthy volunteers. J Clin Psychopharmacol 2004;24(3):268-76
   PubMed Web of Science ®Google Scholar
• Preskorn SH, Greenblatt DJ, Harvey AT. Lack of effect of sertraline on the pharmacokinetics of alprazolam. J Clin Psychopharmacol 2000;20(5):585-6
   PubMed Web of Science ®Google Scholar
• Mandrioli R, Mercolini L, Raggi MA. Metabolism of benzodiazepine and non-benzodiazepine anxiolytic-hypnotic drugs: an analytical point of view. Curr Drug Metab 2010;11:815-29
   PubMed Web of Science ®Google Scholar
• Sheehan DV, Sheehan KH, Raj BA. The speed of onset of action of alprazolam-XR compared to alprazolam-CT in panic disorder. Psychopharmacol Bull 2007;40(2):63-81
   PubMed Web of Science ®Google Scholar
• van Harten J, Holland RL, Wesnes K. Influence of multiple-dose administration of fluvoxamine on the pharmacokinetics of the benzodiazepines bromazepam and lorazepam: a randomized, cross-over study. Eur Neuropsychopharmacol 1992;2(3):381-1
   Google Scholar
• Oda M, Kotegawa T, Tsutsumi K, The effect of itraconazole on the pharmacokinetics and pharmacodynamics of bromazepam in healthy volunteers. Eur J Clin Pharmacol 2003;59(8-9):615-19
   PubMed Web of Science ®Google Scholar
• Bareggi SR, Truci G, Leva S, Pharmacokinetics and bioavailability of intravenous and oral chlordesmethyldiazepam in humans. Eur J Clin Pharmacol 1988;34(1):109-12
   PubMed Web of Science ®Google Scholar
• Sennesael J, Verbeelen D, Vanhaelst L, Pharmacokinetics of intravenous and oral chlordesmethyldiazepam in patients on regular haemodialysis. Eur J Clin Pharmacol 1991;41(1):65-8
   PubMed Web of Science ®Google Scholar
• Bareggi SR, Pirola R, Potvin P, Effects of liver disease on the pharmacokinetics of intravenous and oral chlordesmethyldiazepam. Eur J Clin Pharmacol 1995;48(3–4):265-8
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ, Shader RI, MacLeod SM, Clinical pharmacokinetics of chlordiazepoxide. Clin Pharmacokinet 1978;3(5):381-94
   PubMed Web of Science ®Google Scholar
• Vozeh S. Pharmacokinetic of benzodiazepines in old age. Schweiz Med Wochenschr 1981;111(47):1789-93
   PubMedGoogle Scholar
• Niwa T, Shitaga T, Ishii I, Contribution of human hepatic cytochrome P450 isoforms to the metabolism of psychotropic drugs. Biol Pharm Bull 2005;28(9):1711-16
   PubMed Web of Science ®Google Scholar
• Shimada T, Yamazaki H, Mimura M, Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994;270:414-23
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ, Divoll MK, Soong MH, Desmethyldiazepam pharmacokinetics: studies following intravenous and oral desmethyldiazepam, oral clorazepate, and intravenous diazepam. J Clin Pharmacol 1988;28(9):853-9
   PubMed Web of Science ®Google Scholar
• Baselt RC, Cravey RH. Disposition of toxic drugs and chemicals in man. 4th edition. Chemical Toxicology Institute, Foster City;l 1995
   Google Scholar
• de Haro L, Valli M, Bourdon JH, Diazepam poisoning with one month monitoring of diazepam and nordiazepam blood levels. Vet Hum Toxicol 2001;43(3):174-5
   PubMedGoogle Scholar
• Araki K, Yasui-Furukori N, Fukasawa T, Inhibition of the metabolism of etizolam by itraconazole in humans: evidence for the involvement of CYP3A4 in etizolam metabolism. Eur J Clin Pharmacol 2004;60(6):427-30
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Kawashima Y, Shioiri T, Effects of concomitant fluvoxamine on the plasma concentration of etizolam in Japanese psychiatric patients: wide interindividual variation in the drug interaction. Ther Drug Monit 2004;26(6):638-42
   PubMed Web of Science ®Google Scholar
• Kondo S, Fukasawa T, Yasui-Furukori N, Induction of the metabolism of etizolam by carbamazepine in humans. Eur J Clin Pharmacol 2005;61(3):185-8
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ. Clinical pharmacokinetics of oxazepam and lorazepam. Clin Pharmacokinet 1981;6(2):89-105
   PubMed Web of Science ®Google Scholar
• Papini O, Pereira Da Cunha S, Do Carno Da Silva Mathes A, Kinetic disposition of lorazepam with focus on the glucuronidation capacity, transplacental transfer in parturients and racemization in biological samples. J Pharm Biomed 2006;40(2):397-403
   PubMed Web of Science ®Google Scholar
• Sawamura R, Sato H, Kawakami J, Inhibitory effect of azole antifungal agents on the glucuronidation of lorazepam using rabbit liver microsomes in vitro. Biol Pharm Bull 2000;23(5):669-71
   PubMed Web of Science ®Google Scholar
• Shader RI, Pary RJ, Harmatz JS, Plasma concentrations and clinical effects after single oral doses of prazepam, clorazepate, and diazepam. J Clin Psychiatry 1984;45(10):411-13
   PubMed Web of Science ®Google Scholar
• Altamura AC, Mauri MC, Mantero M, Brunetti M. Clonazepam/haloperidol combination therapy in schizophrenia: a double blind study. Acta Psychiatr Scand 1987;76:702-6
   PubMed Web of Science ®Google Scholar
• Van Ameringen M, Mancini C, Pipe B, Antiepileptic drugs in the treatment of anxiety disorders: role in therapy. Drugs 2004;64(19):2199-220
   PubMed Web of Science ®Google Scholar
• Lesser H, Sharma U, LaMoreaux L, Poole RM. Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. Neurology 2004;63:2104-10
   PubMed Web of Science ®Google Scholar
• Dworkin RH, Corbin AE, Young JP Jr, Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology 2003;60:1274-83
   PubMed Web of Science ®Google Scholar
• Arroyo S, Anhut H, Kugler AR, Pregabalin 1008-011 International Study Group. Pregabalin add-on treatment: a randomized, double-blind, placebo-controlled, dose-response study in adults with partial seizures. Epilepsia 2004;45:20-7
   PubMed Web of Science ®Google Scholar
• Dobrea C, Buoli M, Arici C, Tolerability and use in co-administration of pregabalin in affective patients: a 6-month prospective naturalistic study. Expert Opin Drug Saf 2012;11(6):893-9
   PubMed Web of Science ®Google Scholar
• Rickels K, Pollack MH, Feltner DE, Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch Gen Psychiatry 2005;62(9):1022-30
   PubMed Web of Science ®Google Scholar
• Strawn JR, Geracioti TD Jr. The treatment of generalized anxiety disorder with pregabalin, an atypical anxiolytic. Neuropsychiatr Dis Treat 2007;3(2):237-43
   PubMedGoogle Scholar
• Lauria-Horner BA, Pohl RB. Pregabalin: a new anxiolytic. Expert Opin Investig Drugs 2003;12(4):663-72
   PubMed Web of Science ®Google Scholar
• Montgomery SA. Pregabalin for the treatment of generalised anxiety disorder. Expert Opin Pharmacother 2006;7(15):2139-54
   PubMed Web of Science ®Google Scholar
• Hadley SJ, Mandel FS, Schweizer E. Switching from long-term benzodiazepine therapy to pregabalin in patients with generalized anxiety disorder: a double-blind, placebo-controlled trial. J Psychopharmacol 2012;26(4):461-70
   PubMed Web of Science ®Google Scholar
• Shneker BF, McAuley JW. Pregabalin: a new neuromodulator with broad therapeutic indications. Ann Pharmacother 2005;39(12):2029-37
   PubMed Web of Science ®Google Scholar
• Bockbrader HN, Radulovic LL, Posvar EL, Clinical pharmacokinetics of pregabalin in healthy volunteers. J Clin Pharmacol 2010;50(8):941-50
   PubMed Web of Science ®Google Scholar
• Bockbrader HN, Wesche D, Miller R, A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. Clin Pharmacokinet 2010;49(10):661-9
   PubMed Web of Science ®Google Scholar
• Ben-Menachem E. Pregabalin pharmacology and its relevance to clinical practice. Epilepsia 2004;45(Suppl 6):13-18
   PubMed Web of Science ®Google Scholar
• Feng MR, Turluck D, Burleigh J, Brain microdialysis and PK/PD correlation of pregabalin in rats. Eur J Drug Metab Pharmacokinet 2001;26(1-2):123-8
   PubMed Web of Science ®Google Scholar
• Shoji S, Suzuki M, Tomono Y, Population pharmacokinetics of pregabalin in healthy subjects and patients with post-herpetic neuralgia or diabetic peripheral neuropathy. Br J Clin Pharmacol 2011;72(1):63-76
   PubMed Web of Science ®Google Scholar
• Corrigan BW, Pool WF, Posvar EL, Metabolic disposition of pregabalin in healthy volunteers. Clin Phar Ther 2001;69:18
   Web of Science ®Google Scholar
• Randinitis EJ, Posvar EL, Alvey CW, Pharmacokinetics of pregabalin in subjects with various degrees of renal function. J Clin Pharmacol 2003;43(3):277-83
   PubMed Web of Science ®Google Scholar
• Devi P, Madhu K, Ganapathy B, Evaluation of efficacy and safety of gabapentin, duloxetine, and pregabalin in patients with painful diabetic peripheral neuropathy. Indian J Pharmacol 2012;44(1):51-6
   PubMed Web of Science ®Google Scholar
• Ramsay RE. Clinical efficacy and safety of gabapentin. Neurology 1994;44(6 Suppl 5):S23-30; discussion S31-2
   PubMed Web of Science ®Google Scholar
• Pollack MH, Matthews J, Scott EL. Gabapentin as a potential treatment for anxiety disorders. Am J Psychiatry 1998;155(7):992-3
   PubMed Web of Science ®Google Scholar
• Obrocea GV, Dunn RM, Frye MA, Clinical predictors of response to lamotrigine and gabapentin monotherapy in refractory affective disorders. Biol Psychiatry 2002;51(3):253-60
   PubMed Web of Science ®Google Scholar
• Dougherty JA, Rhoney DH. Gabapentin: a unique anti-epileptic agent. Neurol Res 2001;23(8):821-9
   PubMed Web of Science ®Google Scholar
• Stewart BH, Kugler AR, Thompson PR, Bockbrader HN. A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of the lack of proportionality between increasing dose and drug levels in plasma. Pharm Res 1993;10:276-81
   PubMed Web of Science ®Google Scholar
• Vollmer KO, Anhur H, Thomann I, Pharmacokinetic model and absolute bioavailability of new anticonvulsant gabapentin. Adv Epileptol 1987;17:209-11
   Google Scholar
• Turck D, Vollmer KO, Bockbrader H, Sedman A. Dose-linearity of the new anticonvulsant gabapentin after multiple oral doses. Eur J Clin Pharmacol 1989;36(Suppl A):310
   Google Scholar
• Bruni J. Gabapentin. Can J Neurol Sci 1996;23:S10-12
   PubMed Web of Science ®Google Scholar
• McLean MJ. Gabapentin. Epilepsia 1995;36(Suppl 2):S73-86
   PubMedGoogle Scholar
• Gidal BE, Radulovic LL, Kruger S, Inter- and intra-subject variability in gabapentin absorption and absolute bioavailability. Epilepsy Res 2000;40(2-3):123-7
   PubMed Web of Science ®Google Scholar
• Blum RA, Comstock TJ, Sica DA, Pharmacokinetics of gabapentin in subjects with various degrees of renal function. Clin Pharmacol Ther 1994;56:154-9
   PubMed Web of Science ®Google Scholar
• Rose MA, Kam PC. Gabapentin: pharmacology and its use in pain management. Anaesthesia 2002;57(5):451-62
   PubMed Web of Science ®Google Scholar
• Semanchuk MR, Labiner DM. Gabapentin and lamotrigine: prescribing guidelines for psychiatry. J Pract Psychiatry Behav Health 1997;3:334-42
   Google Scholar
• Wong MO, Eldon MA, Keane WF, Disposition of gabapentin in anuric subjects on hemodialysis. J Clin Pharmacol 1995;35:622-6
   PubMed Web of Science ®Google Scholar
• Ouellet D, Bockbrader HN, Wesche DL, Population pharmacokinetics of gabapentin in infants and children. Epilepsy Res 2001;47:229-41
   PubMed Web of Science ®Google Scholar
• Busch JA, Radulovic LL, Bockbrader HN, Effect of Maalox TC on single-dose pharmacokinetics of gabapentin capsules in healthy subject. Pharm Res 1992;9(Suppl):S-315
   Google Scholar
• Muscas GC, Chiroli S, Luceri F, Conversion from thrice daily to twice daily administration of gabapentin (GBP) in partial epilepsy: analysis of clinical efficacy and plasma levels. Seizure 2000;9(1):47-50
   PubMed Web of Science ®Google Scholar
• Eison MS, Eison AS. Buspirone as a midbrain modulator: anxiolysis unrelated to traditional benzodiazepine mechanisms. Drug Dev Res 1984;4(1):109-19
   Web of Science ®Google Scholar
• Fulton B, Brogden RN. Buspirone – an updated review of its clinical pharmacology and therapeutic applications. CNS Drugs 1997;7:68-88
   Web of Science ®Google Scholar
• Rickles K. Buspirone in clinical practice. J Clin Psychiatry 1990;51(Suppl 9):51-4
   Google Scholar
• Schatzberg AF, Cole JO, Debattista C. Manual of clinical psychopharmacology. 7th edition. American Psychiatric Publishing, Arlington; 2010
   Google Scholar
• Mayol RF, Adamson DS, Gammans RE, Pharmacokinetics and disposition of 14C-buspirone HCl after intravenous and oral dosing in man [abstract no. B36]. Clin Pharmacol Ther 1985;37:210
   Web of Science ®Google Scholar
• Zhu M, Zhao W, Jimenez H, Cytochrome P450 3A-mediated metabolism of buspirone in human liver microsomes. Drug Metab Dispos 2005;33(4):500-7
   PubMed Web of Science ®Google Scholar
• Gammans RE, Mayol RF, Labudde JA. Metabolism and disposition of buspirone. Am J Med 1986;80(Suppl 3b):41-51
   PubMed Web of Science ®Google Scholar
• Gammans RE, Mayol RF, Mackenthum AV, The relationship between buspirone bioavailability and dose in healthy subjects. Biopharm Disp 1985;6:139-45
   PubMed Web of Science ®Google Scholar
• Mahmood I, Sahajwalla C. Clinical pharmacokinetics and pharmacodynamics of buspirone, an anxiolytic drug. Clin Pharmacokinet 1999;36(4):277-87
   PubMed Web of Science ®Google Scholar
• Jajoo HK, Mayol RF, LaBudde JA, Metabolism of the antianxiety drug buspirone in human subjects. Drug Metab Dispos 1989;17:634-40
   PubMed Web of Science ®Google Scholar
• Kivistö KT, Lamberg TS, Kantola T, Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole. Clin Pharmacol Ther 1997;62(3):348-54
   PubMed Web of Science ®Google Scholar
• Huffman JC, Stern TA. Neuropsychiatric consequences of cardiovascular medications. Dialogues Clin Neurosci 2007;9:29-45
   PubMedGoogle Scholar
• Heim A, Vanelle JM. Relevant pharmacologic data as a guide for use of beta-blockers in psychiatry. Encephale 1992;18(6):665-7
   PubMedGoogle Scholar
• Benet LZ, Oie S, Schwartz JB. Design and optimization of dosage regimens; pharmacokinetic data. In: Hardman JG, Limbird LE, Molinoff PB, Rudden RW, Goodman Gilman A, editors. Goodman & Gilman's the pharmacological basis of therapeutics. McGraw-Hill, New York; 1996
   Google Scholar
• Turner P. Clinical psychopharmacology of beta-adrenoceptor antagonism in treatment of anxiety. Ann Acad Med Singapore 1991;20(1):43-5
   PubMedGoogle Scholar
• Huh J, Goebert D, Takeshita J, Treatment of generalized anxiety disorder: a comprehensive review of the literature for psychopharmacologic alternatives to newer antidepressants and benzodiazepines. Prim Care Companion CNS Disord 2011;13:2-18
   Google Scholar
• Noyes R Jr. Beta-adrenergic blocking drugs in anxiety and stress. Psychiatr Clin North Am 1985;8(1):119-32
   PubMed Web of Science ®Google Scholar
• Tyrer P. Current status of beta-blocking drugs in the treatment of anxiety disorders. Drugs 1988;36(6):773-83
   PubMed Web of Science ®Google Scholar
• Russo ME, Covinsky JO. Oxprenolol hydrochloride: pharmacology, pharmacokinetics, adverse effects and clinical efficacy. Pharmacotherapy 1983;3(2 Pt 1):68-81
   PubMed Web of Science ®Google Scholar
• Schneier FR. Clinical Practice. Social anxiety disorder. N Engl J Med 2006;355(10):1029-36
   PubMed Web of Science ®Google Scholar
• Peet M. The treatment of anxiety with beta-blocking drugs. Postgrad Med J 1988;64(Suppl 2):45-9
   PubMedGoogle Scholar
• Aouizerate B, Martin-Guehl C, Tignol J. Neurobiology and pharmacotherapy of social phobia. Encephale 2004;30(4):301-13
   PubMed Web of Science ®Google Scholar
• Fagerström KO, Hugdahl K, Lundström N. Effect of beta-receptor blockade on anxiety with reference to the three-systems model of phobic behavior. Neuropsychobiology 1985;13(4):187-93
   PubMed Web of Science ®Google Scholar
• Davidson JR. Pharmacotherapy of social anxiety disorder: what does the evidence tell us? J Clin Psychiatry 2006;67(Suppl 12):20-6
   PubMed Web of Science ®Google Scholar
• Hayes PE, Schulz SC. The use of beta-adrenergic blocking agents in anxiety disorders and schizophrenia. Pharmacotherapy 1983;3(2 Pt 1):101-17
   PubMed Web of Science ®Google Scholar
• Brunet A, Orr SP, Tremblay J, Effect of post-retrieval propranolol on psychophysiologic responding during subsequent script-driven traumatic imagery in post-traumatic stress disorder. J Psychiatr Res 2008;42(6):503-6
   PubMed Web of Science ®Google Scholar
• Fourneret P, Desombre H, de Villard R, Revol O. Interest of propranolol in the treatment of school refusal anxiety: about three clinical observations. Encephale 2001;27(6):578-84
   PubMed Web of Science ®Google Scholar
• Paykel ES, Fleminger R, Watson JP. Psychiatric side effects of antihypertensive drugs other than reserpine. J Clin Psychopharmacol 1982;2:14-39
   PubMed Web of Science ®Google Scholar
• Chidsey CA, Marselli P, Bianchetti G, Studies of the absorption and removal of propranolol in hypertensive patients during therapy. Circulation 1975;52:313-18
   PubMed Web of Science ®Google Scholar
• Melander A, Danielson K, Schersten B, Enhancement of the bio- availability of propranolol and metoprolol by food. Clin Pharmacol Ther 1977;22:108-12
   PubMed Web of Science ®Google Scholar
• Wood AJJ, Carr K, Vestal RE, Direct measurement of propranolol bioavailability during accumulation to steady state. Br J Clin Pharmacol 1978;6:345-50
   PubMed Web of Science ®Google Scholar
• Hao J, Yang MB, Liu H, Distribution of propranolol in periocular tissues: a comparison of topical and systemic administration. J Ocul Pharmacol Ther 2011;27(5):453-9
   PubMed Web of Science ®Google Scholar
• Ritschel WA. Handbook of basic pharmacokinetics. 3rd edition. Drug Intelligence Publications, Bethesda; 1986
   Google Scholar
• Johnsson G, Regardh C-G. Clinical pharmacokinetics of beta-adrenoceptor blocking drugs. Clin Pharmacokinet 1976;1:233-63
   PubMedGoogle Scholar
• Beckett AH, Triggs EJ. Buccal absorption of basic drugs and its application as an in vivo model of passive drug transfer through lipid membranes. J Pharm Pharmacol 1967;19(Suppl S):S-31-41
   PubMedGoogle Scholar
• Holford NHG, Sheiner LB. Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. Clin Pharmacokinet 1981;6:429-53
   PubMed Web of Science ®Google Scholar
• Cid E, Mella F, Lucchini L, Plasma concentrations and bioavailability of propranolol by oral, rectal and intravenous administration in man. Biopharm Drug Dispos 1986;7:559-66
   PubMed Web of Science ®Google Scholar
• Johnsson G, Regàrdh CG. Clinical pharmacokinetics of beta-adrenoreceptor blocking drugs. Clin Pharmacokinet 1976;1(4):233-63
   PubMedGoogle Scholar
• Walle U, Walle T, Bai S, Stereoselective binding of propranolol to human plasma, alpha1-acid glycoprotein, and albumin. Clin Pharmacol Ther 1983;34:718-23
   PubMed Web of Science ®Google Scholar
• Gilmore D, Gal J, Gerber J, Age and gender influence the stereoselective pharmacokinetics of propranolol. J Pharmacol Exp Ther 1992;261:1181-6
   PubMed Web of Science ®Google Scholar
• Borchard U. Pharmacokinetics of beta-adrenoceptor blocking agents: clinical significance of hepatic and/or renal clearance. Clin Physiol Biochem 1990;8(Suppl 2):28-34; Review
   PubMedGoogle Scholar
• Brunton L, Chabner B, Knollmann B. Goodman & Gilman's the pharmacological basis of therapeutics. 12th edition. The McGraw-Hill Companies, New York; 2011
   Google Scholar
• Kendall MJ. Clinical relevance of pharmacokinetic differences between beta-blockers. Am J Cardiol 1997;80(9B):15J-9J; Review
   PubMed Web of Science ®Google Scholar
• Agon P, Goethals P, Van Haver D, Permeability of the blood–brain barrier for atenolol studied by positron emission tomography. J Pharm Pharmacol 1991;43(8):597-600
   PubMed Web of Science ®Google Scholar
• Sheetal Ladva (2006-06-30). Updated NICE guideline on the management of hypertension in adults in primary care. National Institute for Health and Clinical Excellence, London; Retrieved 2009-02-03
   Google Scholar
• Talbert RL. Pharmacokinetics and pharmacodynamics of beta-blockers in heart failure. Heart Fail Rev 2004(2):131-7
   PubMed Web of Science ®Google Scholar
• Fitzgerald JD, Ruffin R, Smedstad KG, Studies on the pharmacokinetics and pharmacodynamics of atenolol in man. Eur J Clin Pharmacol 1978;13(2):81-9
   PubMed Web of Science ®Google Scholar
• Mehvar R, Gross ME, Kreamer RN. Pharmacokinetics of atenolol enantiomers in human. J Pharm Sci 1990;79(10):881-5
   PubMed Web of Science ®Google Scholar
• Wan SH, Koda RT, Maronde RF. Pharmacokinetics, pharmacology of atenolol and effect of renal disease. Br J Clin Pharmacol 1979;7(6):569-74
   PubMed Web of Science ®Google Scholar
• Donaldson M, Gizzarelli G, Chanpong B. Oral sedation: a primer on anxiolysis for the adult patient. Anesth Prog 2007;54:118-29
   PubMedGoogle Scholar
• Kubo N, Shirakawa O, Kuno T, Antimuscarinic effects of antihistamines: quantitative evaluation by receptor-binding assay. Jpn J Pharmacol 1987;43(3):277-82
   PubMedGoogle Scholar
• Llorca PM, Spadone C, Sol O, Efficacy and safety of hydroxyzine in the treatment of generalized anxiety disorder: a 3-month double-blind study. J Clin Psychiatry 2002;63(11):1020-7
   PubMed Web of Science ®Google Scholar
• Needleman HL, Joshi A, Griffith DG. Conscious sedation of pediatric dental patients using chloral hydrate, hydroxyzine, and nitrous oxide – a retrospective study of 382 sedations. Pediatr Dent 1995;17(7):424-31
   PubMedGoogle Scholar
• Woodward JK. Pharmacology of antihistamines. J Allergy Clin Immunol 1990;86(4 Pt 2):606-12
   PubMed Web of Science ®Google Scholar
• Simons FE, Simons KJ, Frith EM. The pharmacokinetics and antihistaminic of the H1 receptor antagonist hydroxyzine. J Allergy Clin Immunol 1984;73(1 Pt 1):69-75
   PubMed Web of Science ®Google Scholar
• Simons FE, Simons KJ, Chung M, The comparative pharmacokinetics of H1-receptor antagonists. Ann Allergy 1987;59(6 Pt 2):20-4
   PubMedGoogle Scholar